Generic Name and Formulations:
Dicloxacillin sodium 250mg, 500mg; caps.
Various generic manufacturers
Indications for Dicloxacillin :
Susceptible infections caused by penicillinase-producing staphylococci. Not for initial therapy in serious, life-threatening infections.
Take on an empty stomach. ≥40kg: Mild to moderate infections: 125mg every 6hrs. Severe infections: 250mg every 6hrs.
Take on an empty stomach. <40kg: Mild to moderate infections: 12.5mg/kg/day in divided doses every 6hrs. Severe: 25mg/kg/day in divided doses every 6hrs.
Signficant allergy/asthma. Monitor blood, renal, and hepatic function in long-term use. Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Avoid concomitant tetracyclines, aminoglycosides. Serum levels increased by probenecid. May reduce anticoagulant response: monitor PT.
GI upset, hypersensitivity reactions, neurotoxic reactions, blood dyscrasias; C. difficile associated diarrhea.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|